慢阻肺是我国乃至全球主要的公共卫生问题之一,随着人口老龄化和环境因素不断变化,预计未来几十年该疾病负担将继续增长。根据全球疾病负担数据库建模估计,2020—2050年,全球25岁及以上人群慢阻肺的病例数量将增加23%;到2050年,全球有接近6亿慢阻肺病患者。尽管在呼吸药物领域尚未诞生如GLP-1类药物引起广泛关注的突破性品种,然而,庞大的病人基数给这一赛道带来巨大的想象空间。有机构预测,2032...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.